

Abstract of the disclosure

The present invention ~~relates to~~ provides pharmaceutical compositions for sustained release comprising as active ingredient an HMG-CoA reductase inhibitor or a pharmaceutically acceptable salt thereof[.,.] said The compositions comprising have a core consisting of an inner phase (internal) and an outer phase (external) ~~wherein~~ ~~the outer phase does not comprise a matrix former and~~ ~~wherein~~ the core is first coated with a non functional film coat and then with an enteric coat.